Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
FLAURA study of osimertinib versus TKI for 1st line NSCLC

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 892

Dr Suresh Ramalingam - Winship Cancer Institute, Druid Hills, USA

Dr Suresh Ramalingam presents in a press conference at ESMO 2017 data from the randomised phase III FLAURA study looking at the use of osimertinib versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or metastatic Non Small Cell Lung Cancer. 

For more on this study, read our news coverage here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence